Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1b study results for its CAR T-cell therapy, JNJ-90014496, ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Research shows that the drug tazemetostat – which is already approved for use in patients with one type of B-cell lymphoma – ...

The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...